Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 298

Sort by

Sort Order Select

Journal Articles

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Blood (2025) 146 (Supplement 1): 4069.

https://doi.org/10.1182/blood-2025-4069

Published: 2025

Journal Articles

Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.

Blood (2025) 146 (Supplement 1): 4066.

https://doi.org/10.1182/blood-2025-4066

Published: 2025

Journal Articles

Melphalan weight-based dosing in overweight and obese patients undergoing autologous transplant for multiple myeloma

Anmol Goyal, Daniel Cancilla, Wei Wei, Danielle Cenin, Faiz Anwer, Claudio Brunstein, Shahzad Raza, Louis Williams, Jack Khouri

Blood (2025) 146 (Supplement 1): 4033.

https://doi.org/10.1182/blood-2025-4033

Published: 2025

Journal Articles

Underexplored mutations in plasma cell myeloma

Kirti Arora, Diana Basali, Yasar Shad, Akriti Jain, Christy Samaras, Haleema Sadia Adil, Jason Valent, Louis Williams, Jack Khouri, Sandra Mazzoni, Faiz Anwer, Abhay Singh, Shahzad Raza

Blood (2025) 146 (Supplement 1): 4025.

https://doi.org/10.1182/blood-2025-4025

Published: 2025

Journal Articles

Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial

Anna Sureda Balarí, Abdullah Khan, Albert Oriol, Mercedes Gironella Mesa, Faiz Anwer, Cristina Encinas, Brea Lipe, Paula Rodriguez-Otero, Ping Chen, Hongxia Lin, Kexin Jin, Thomas Solomon, Lilia Taningco, Olumoroti Aina, Paulo Maciag, Sagar Lonial

Blood (2025) 146 (Supplement 1): 5810.

https://doi.org/10.1182/blood-2025-5810

Published: 2025

Journal Articles

Targeting inflammation in sickle cell disease: Association of GLP-1 agonist use with improved survival and reduced sickle cell crisis and cardiopulmonary complications

Asfand Yar Cheema, Mishaal Munir, Aashray Mandala, Shrishti Sinha, Junho Song, Zaigham ul Islam, Utkarsh Acharya, Faiz Anwer

Blood (2025) 146 (Supplement 1): 2970.

https://doi.org/10.1182/blood-2025-2970

Published: 2025

Journal Articles

Therapeutic trade-offs between ide-cel and cilta-cel in RRMM: A meta-analytic comparison of efficacy and adverse events

Mobina Golmohammadi, Shahzad Raza, Doris Hansen, Sandra Mazzoni, Louis Williams, Kirti Arora, Haleema Sadia Adil, Faiz Anwer, Majid Jaberi

Blood (2025) 146 (Supplement 1): 7606.

https://doi.org/10.1182/blood-2025-7606

Published: 2025

Journal Articles

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

Blood (2025) 146 (Supplement 1): 2814.

https://doi.org/10.1182/blood-2025-2814

Published: 2025

Journal Articles

Trends in triplet and quadruplet regimen utilization among patients with newly diagnosed multiple myeloma during 2017-2024

Hamlet Gasoyan, Michael Rothberg, Jeffrey Kovach, Nicholas Casacchia, Brittany Peterre, Ming Wang, Jason Valent, Faiz Anwer

Blood (2025) 146 (Supplement 1): 2626.

https://doi.org/10.1182/blood-2025-2626

Published: 2025

Journal Articles

Real-world utilization patterns of bone-modifying agents for multiple myeloma in the era of novel therapies

Hamlet Gasoyan, Michael Rothberg, Jeffrey Kovach, Nicholas Casacchia, Hossam M. Ali, Yara Shatnawi, Brittany Peterre, Ming Wang, Jason Valent, Faiz Anwer

Blood (2025) 146 (Supplement 1): 4402.

https://doi.org/10.1182/blood-2025-4402

Published: 2025

Journal Articles

Risk of cardiovascular disease-related mortality in hematologic malignancy patients: A population-level US retrospective cohort study, 1975-2022

Husayn Ladha, Hetty Carraway, Aaron Gerds, Abhay Singh, Anjali Advani, Moaath Mustafa Ali, John Molina, Sophia Balderman, Akriti Jain, Faiz Anwer, Sudipto Mukherjee

Blood (2025) 146 (Supplement 1): 4497.

https://doi.org/10.1182/blood-2025-4497

Published: 2025

Journal Articles

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies

Agrima Mian, Rafaella Ferreira De Araujo Litvin, Jessica Colon-Franco, Sujata Patil, Megan Molnar, Allison Winter, Sandra Mazzoni, Robert Dean, Louis Williams, Aaron Gerds, John Molina, Shahzad Raza, Faiz Anwer, Deepa Jagadeesh, Betty K. Hamilton, Claudio Brunstein, Brian Hill, Paolo Caimi

Blood (2025) 146 (Supplement 1): 2397.

https://doi.org/10.1182/blood-2025-2397

Published: 2025

Journal Articles

Talquetamab outcomes in relapsed/refractory myeloma with extramedullary and paraskeletal soft tissue plasmacytomas

Blood (2025) 146 (Supplement 1): 825.

https://doi.org/10.1182/blood-2025-825

Published: 2025

Journal Articles

Dysregulated proteasome proteostasis acts as a driver of light chain amyloidosis

Sandra Mazzoni, Babal Jha, Louis Williams, Jack Khouri, Christy Samaras, Shahzad Raza, Faiz Anwer, Jason Valent, Arda Durmaz, Yahan Zhang, Kacey O'Donnell

Blood (2025) 146 (Supplement 1): 7473.

https://doi.org/10.1182/blood-2025-7473

Published: 2025

Journal Articles

Subsequent primary malignancies after CAR-T therapy: A study from the US multiple myeloma immunotherapy consortium

Blood (2025) 146 (Supplement 1): 5852.

https://doi.org/10.1182/blood-2025-5852

Published: 2025

Journal Articles

Prognostic factors and survival outcomes of urgent inpatient chemotherapy for relapsed/refractory lymphoma in the modern era

Abhishek Kataria, Mikhaila Rice, Wei Wei, Faiz Anwer, Paolo Caimi, Allison Winter, Robert Dean, Taylor Brooks, Joslyn Rudoni, Jack Khouri, Christy Samaras, Shahzad Raza, Sandra Mazzoni, Jason Valent, Brian Hill, Deepa Jagadeesh

Blood (2025) 146 (Supplement 1): 2737.

https://doi.org/10.1182/blood-2025-2737

Published: 2025

Journal Articles

Patients with multiple myeloma and CKD: Should we really hold off on bispecific therapy in this subgroup?

Kirti Arora, Rishi Chowdhary, Diana Basali, Christy Samaras, Akriti Jain, Deevyashali Parekh, Jason Valent, Jack Khouri, Louis Williams, Sandra Mazzoni, Abhay Singh, Faiz Anwer, Shahzad Raza

Blood (2025) 146 (Supplement 1): 2248.

https://doi.org/10.1182/blood-2025-2248

Published: 2025

Journal Articles

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Doris Hansen, Lauren Peres, Danai Dima, Saurabh Zanwar, Omar Alexis Castaneda Puglianini, Alicia Richards, Mahmoud Gaballa, Oren Pasvolsky, Aimaz Afrough, Brett Reid, Ariel Grajales-Cruz, Zhuoer Xie, Utkarsh Goel, Aishwarya Sannareddy, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Hitomi Hosoya, Lekha Mikkilineni, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Peter Cheng, Christian Gordillo, Eli Zolotov, Evguenia Bhurtel, Jeries Kort, Raffaella Cassano Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Rahul Banerjee, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Frederick Locke, Yi Lin, Surbhi Sidana, Krina Patel

Blood (2025) 146 (Supplement 1): 93.

https://doi.org/10.1182/blood-2025-93

Published: 2025

Journal Articles

Aberrant clonal plasma cells bypass the proteasome proteostasis by endoplasmic reticulum associated protein degradation

Yahan Zhang, Sandra Mazzoni, Arda Durmaz, Kacey O'Donnell, Christy Samaras, Faiz Anwer, Shahzad Raza, Jason Valent, Jack Khouri, Louis Williams, Babal Jha

Blood (2025) 146 (Supplement 1): 7476.

https://doi.org/10.1182/blood-2025-7476

Published: 2025

Journal Articles

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Surbhi Sidana, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Alexis Castaneda Puglianini, Gabriel De Avila, Christian Gordillo, Eli Zolotov, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen

Blood (2025) 146 (Supplement 1): 1034.

https://doi.org/10.1182/blood-2025-1034

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.

Melphalan weight-based dosing in overweight and obese patients undergoing autologous transplant for multiple myeloma

Underexplored mutations in plasma cell myeloma

Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial

Targeting inflammation in sickle cell disease: Association of GLP-1 agonist use with improved survival and reduced sickle cell crisis and cardiopulmonary complications

Therapeutic trade-offs between ide-cel and cilta-cel in RRMM: A meta-analytic comparison of efficacy and adverse events

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

Trends in triplet and quadruplet regimen utilization among patients with newly diagnosed multiple myeloma during 2017-2024

Real-world utilization patterns of bone-modifying agents for multiple myeloma in the era of novel therapies

Risk of cardiovascular disease-related mortality in hematologic malignancy patients: A population-level US retrospective cohort study, 1975-2022

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies

Talquetamab outcomes in relapsed/refractory myeloma with extramedullary and paraskeletal soft tissue plasmacytomas

Dysregulated proteasome proteostasis acts as a driver of light chain amyloidosis

Subsequent primary malignancies after CAR-T therapy: A study from the US multiple myeloma immunotherapy consortium

Prognostic factors and survival outcomes of urgent inpatient chemotherapy for relapsed/refractory lymphoma in the modern era

Patients with multiple myeloma and CKD: Should we really hold off on bispecific therapy in this subgroup?

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Aberrant clonal plasma cells bypass the proteasome proteostasis by endoplasmic reticulum associated protein degradation

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only